GENOVIS SIGNS DISTRIBUTION AGREEMENT WITH BIOLEGIO

Genovis has developed unique technological aids for medical research. In September 2007 the products were ready to be marketed to customers. Since then Genovis is engaged in introducing the products to customers and continues to expand its sales channels in Europe.

To date Genovis has signed agreements with distributors for the Korean, Swedish, Danish, British, Irish, Spanish, and Portuguese markets. Genovis works through its subsidiary Genovis Inc in the United States.

Through this latest distribution agreement Genovis is taking another important step in its expansion on the European market.

“During this summer we have worked with two reference projects in the Netherlands and Biolegio, with it’s effective and well trained teem, has been a valuable link in these projects. Central Europe is a most important market to us and I look forward to start working towards customers together with Biolegio as distributor”, sais Sarah Fredriksson, CEO Genovis

Biolegio is a Dutch oligonucleotide synthesis company, founded in 1996. Being in the business for over ten years Biolegio has obtained great experience in the oligo synthesis market. Biolegio supplies high quality DNA/RNA oligos, probes and siRNAs to academic hospital, universities and biotechnology company’s throughout Europe. With a well educated and trained team, Biolegio provides superior quality and service.

” Next to the synthesis facility, Biolegio Lab Equipment is a distributor for small bench equipment for the molecular research market. Genovis will fit our product range perfectly thinking of our siRNA synthesis. We look forward to work together with Genovis, since we are looking for high quality products to fit our product range. All products that we are distributing must qualify our customers needs concerning quality and the service they are used to from our own synthesis facility. We think Genovis will open new perspectives in transfection and this will give Biolegio an even stronger position in the research market”, says Ruud van der Steen, CEO